Patent Application
20120245108
The present invention relates to a method of modulating complement factor B (CFB) expression in cells.
In recent years, the destruction of the ozone layer raises the levels of solar ultraviolet (UV) radiation that threatens human health. UV radiation forms part of the electromagnetic spectrum with wavelengths between 200 nm and 400 nm. UV radiation can be divided into three categories dependent on the wavelengths: long wave UVA (320-400 nm), medial wave UVB (280-320 nm), and short wave UVC (200-280 nm). UV radiation can damage the ocular tissues (Galichanin K, Löfgren S, Bergmanson J, Söderberg P. Evolution of damage in the lens after in vivo close to threshold exposure to UV-B radiation: cytomorphological study of apoptosis. Exp Eye Res. 2010 September; 91(3):369-77) and has a phototoxic effect on the retinal pigment epithelium (RPE) cells (Patton W P, Chakravarthy U, Davies R J, Archer D B. Comet assay of UV-induced DNA damage in retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 1999; 40:3268-3275). The RPE is the site of primary injury by near-UV (300-400 nm) radiation and UV-induced damage may be associated with age-related macular degeneration (AMD) (Szaflik J P, Janik-Papis K, Synowiec E, et al. DNA damage and repair in age-related macular degeneration. Mutat Res 2009; 669:169-176).
AMD is the most frequent cause of irreversible blindness in the elder (Almeida L N, Carolino R M, Sperandio D C, Nehemy M B, De Marco L A. The role of molecular genetic factors in age-related macular degeneration. Arq Bras Oftalmol 2009; 72:567-572). Previous studies have shown that complement factors B (CFB) and H (CFH) play an important role in the pathogenesis of AMD in more than 50% of cases (Maller J, George S, Purcell S, et al. Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nat Genet 2006; 38:1055-1059; Gold B, Merriam J E, Zernant J, et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet 2006; 38:458-462). CFB and CFH are involved in body's immune and inflammatory response. Pro-inflammatory cytokines are important mediators of cellular activities for several ocular diseases. For example, pro-inflammatory cytokine interleukin-6 (IL-6) plays a role in inflammation of RPE (Qin S, Ni M, De Vries G W. Implication of S-adenosylhomocysteine hydrolase in inhibition of TNF-alpha and IL-1beta-induced expression of inflammatory mediators by AICAR in RPE cells. Invest Ophthalmol Vis Sci 2008; 49:1274-1281). UVB radiation can induce the IL-6 expression that causes intracellular signaling in cultured human pterygium epithelial cells (Di Girolamo N, Wakefield D, Coroneo M T. UVB-mediated induction of cytokines and growth factors in pterygium epithelial cells involves cell surface receptors and intracellular signaling. Invest Ophthalmol Vis Sci 2006; 47:2430-2437). IL-6 can bind to its receptor (such as gp130) to activate the Janus kinase (JAK) and signal transducer and activator of transcription 3 (STAT-3) pathway to induce expression of several downstream target genes (Murray P J. The JAK-STAT signaling pathway: input and output integration. J Immunol 2007; 178:2623-2629). It has been reported that IL-6 increases the rate of synthesis of CHB mRNA and proteins in fibroblasts (Katz Y, Revel M, Strunk R C. Interleukin 6 stimulates synthesis of complement proteins factor B and C3 in human skin fibroblasts. Eur J Immunol 1989; 19:983-988).
United States Publication No. 2010/0247434 discloses a method of ameliorating or preventing angiogenesis in a mammal comprising administering to the mammal a therapeutically effective amount of gallic acid or its derivatives. Although indicating that angiogenic-associated disease includes age-related macular degeneration and gallic acid derivative includes tannic acid, its experiments do not show the effect of tannic acid on treating macular degeneration. In addition, US 2010/0247434 does not disclose the effect of tannic acid on modulating complement factor B expression.
It remains unclear which signal pathway is involved in UVB-induced IL-6 in RPE.
The present invention relates to a method of modulating complement factor B (CFB) expression in cells, comprising administering an effective amount of tannic acid to the cells.
The present invention is to investigate whether the IL-6/JAK2/STAT3 signaling pathway can be activated by UVB (Ultraviolet B), and whether activation of this pathway can in turn cause CFB (complement factor B) up-regulation in RPE (retinal pigment epithelium) cells. Tannic acid (TA) is also tested as a protective agent from UVB damage to the RPE cells. TA's anti-inflammatory mechanism is also explored in the present invention.
The present invention finds that UVB triggers the IL-6 protein expression, which in turn activates the signal transduction in the IL-6/JAK2/STAT3/CFB pathway leading to up-regulation of CFB (
Component factor B is involved in acute phase inflammatory reaction and its serum levels change significantly in the course of inflammation. CFB is a centrally important component of the alternative complement pathway. Alternative pathway activation results in factor B cleavage leading to the production of Ba and Bb fragments. Both Ba and Bb fragments have been reported to express a variety of biological activities. Several diseases have been linked to CFB such as age-related macular degeneration, complement factor B deficiency, hemolytic uremic syndrome, atherosclerosis, schizophrenia, glomerulonephritis, autoimmune diseases including but not limited to Behçet's syndrome, recurrent oral ulceration and Crohn's disease, uveitis, infectious diseases or fungal infection.
The terms used in the description herein will have their ordinary and common meaning as understood by those skilled in the art, unless specifically defined otherwise. As used throughout the instant application, the following terms shall have the following meanings:
The term “UVB” or “ultraviolet B” refers to one of the three types of invisible light rays (together with ultraviolet A and ultraviolet C) given off by the sun.
The term “disease, disorder or medical condition associated to complement factor B (CFB) expression” refers to the disease, disorder or medical condition that is caused partially or mainly by inappropriate expression of complement factor B (CFB). The disease, disorder or medical condition associated to complement factor B (CFB) expression may includes but not limited to age-related macular degeneration, complement factor B deficiency, hemolytic uremic syndrome, atherosclerosis, schizophrenia, glomerulonephritis, autoimmune diseases such as Behçet's syndrome, recurrent oral ulceration and Crohn's disease, uveitis, infectious diseases or fungal infection.
Thus, the present invention provides a method of modulating complement factor B (CFB) expression in cells, comprising administering an effective amount of tannic acid to the cells. In a preferred embodiment, the method is applied in treating or prophylaxis of the disease, disorder or medical condition associated to complement factor B (CFB) expression, preferably, the disease, disorder or medical condition is selected from age-related macular degeneration, complement factor B deficiency, hemolytic uremic syndrome, atherosclerosis, schizophrenia, glomerulonephritis, autoimmune diseases, uveitis, infectious diseases or fungal infection. Preferably, the disease, disorder or medical condition associated to complement factor B (CFB) expression is age-related macular degeneration. In another preferred embodiment, the complement factor B (CFB) expression is induced by ultraviolet light, preferably by ultraviolet B. In a preferred embodiment, the cells are retinal pigment epithelium cells. In another preferred embodiment, the method modulates CFB expression by modulating STAT3 phosphorylation. Preferably, the method modulates STAT3 phosphorylation by modulating IL-6 protein production.
The examples below are non-limiting and are merely representative of various aspects and features of the present invention.
ARPE-19 (CRL-2302, human retinal pigment epithelial cells, American Type Culture Collection, Manassas, Va.) cells were cultured in 1:1 mixture of Dulbecco's modified Eagle's medium and HAM F-12 nutrient mixture supplemented with 10% fetal bovine serum at 37° C., 5% CO2, and 90% relative humidity. Confluent cells (90% confluence) were used throughout the experiments. Culture materials were obtained from Gibco-BRL (Rockville, Md.). Tannic acid, AG490 and all other reagents were obtained from Sigma Chemical Co. (St. Louis, Mo.).
The source of UVB radiation was performed using the EL series of UV lamp (UVP Inc., San Gabriel, Calif., USA). One hundred percent energy emission was at wavelength 302 nm with a radiation intensity of 1.04 mW/cm2 in a lamp and a target distance of 15 cm was measured by a UVX Digital Radiometer (UVP Inc.).
Trypan blue exclusion assay was used to determine the effect of treatments on the growth and viability of ARPE-19 cells. ARPE-19 cells were plated about 200,000 cells in a 3-cm dish and cultured for 18-24 hours. Cells were exposed to different doses of UVB radiation for 24 hours. After 24 hours, cells were trypsinized and collected in the same tube. The cell pellet was washed and re-suspended in 300 μl PBS (pH 7.4). Trypan blue was added to an equivalent volume (μl) of cell suspension, and the number of cells was counted using a hemacytometer in duplicate for each sample.
The total RNA was isolated from ARPE-19 cells and cells exposed to UVB radiation (5-15 mJ/cm2) for 24 hr using TRIzol Reagent (invitrogen). One μg of total RNA was subject to reverse transcriptase RT-PCR by using RT-PCR kit (Applied Biosystems). The primers used for detecting mRNA for IL-6 were 5′-CCTGCAAG ACCATCGACATG-3′ (forward, SEQ ID NO. 1) and 5′-CTGGCGAGCCTTAGTTTGGA-3′ (reverse, SEQ ID NO. 2); CFB were 5′-TGGTTTGGGAACACAGGAAGGGTA-3′ (forward, SEQ ID NO. 3) and 5′-TCCCTTTGAAGGGCGAATGACTGA-3 (reverse, SEQ ID NO. 4); STAT3 were 5′-GATCCAGTCCGTGGAACCAT-3′ (forward, SEQ ID NO. 5) and 5′-ATAGCCCATGATGATTTCAGCAA-3′ (reverse, SEQ ID NO. 6); JAK2 were 5′-GCTCAGTGGCGGCATGAT-3′ (forward, SEQ ID NO. 7) and 5′-CACTGCCATCCCAAGACATTC-3′ (reverse, SEQ ID NO. 8); GAPDH were 5′-AACAGCGACACCCATCCTC-3′ (forward, SEQ ID NO. 9) and 5′-CATACCAGGAAATGAGCTTGACAA-3′ (reverse, SEQ ID NO. 10). Real-time PCR was performed in a Gene Amp 7900® Sequence Detection System SDS (Applied Biosystems, Foster City, Calif., USA) using SYBR® Green PCR Master Mix Applied Biosystems. The relative gene expression is the comparative CT method. Each sample was normalized on the basis of its GAPDH content according to the formula 2−ΔΔCT.
Total cell lysates were resolved by 10% sodium dodecyl sulfate-polyacryl amide gel electrophoresis, transferred to membranes and blocked, and then probed phospho-STAT3(Tyr705) and STAT3 (Cell Signaling Technology, Danvers, Mass.) antibodies. To control for protein loading, all blots were probed with GAPDH (Millipore, Billerica, Mass.) as well. The bands were detected using the enhanced chemiluminescence system (Millipore, Billerica, Mass.).
ARPE-19 cells were plated about 200,000 cells in a 3-cm dish and cultured for 18-24 hours. Cells were exposed to UVB radiation for 24 hours, 1 ml aliquots of cell culture supernatants were drawn off and frozen at −80° C. ELISAs were carried out with the OptEIA human IL-6 ELISA kit (BD Pharmingen) according to the manufacturer's instructions. Supernatant samples were plated in duplicate wells of a 96-well plate. Freshly diluted rIL-6 which is useful as a standard control was used to generate a standard curve on each plate analyzed. Plates were read at 450 nm using a spectrophotometric plate reader. Raw data were corrected against blank wells and converted to pg/ml using the standard curve. Each sample was normalized on its cell number.
Data of a continuous variable was expressed as the mean±standard deviation (SD). Unpaired t-tests were used to compare means between two groups. A p-value of less than 0.05 was considered statistically significant.
The UVB radiation dose-dependently (0-25 mJ/cm2) decreased cell proliferation at 24 h after radiation (
Effects of UVB Radiation on mRNA Expression of the IL-6/JAK2/STAT3 Pathway
IL-6 binds to cell surface receptors to induce the signal transduction in the JAK2-STAT3 pathway (Sherman C T, Brasier A R. Role of signal transducers and activators of transcription 1 and −3 in inducible regulation of the human angiotensinogen gene by interleukin-6. Mol Endocrinol 2001; 15:441-457). The mRNA abundance of IL-6, JAK2 and STAT3 in response to UVB was detected by the real-time RT-PCR. The UVB radiation dose-dependently (0-15 mJ/cm2) increased IL-6 mRNA at 24 h (
The present invention determined whether UVB can induce IL-6 protein production in the ARPE-19 cell culture supernatants by ELISA. It was found that UVB radiation increased IL-6 protein expression (
IL-6 binds to its receptor gp130 leading to phosphorylation of Tyr705 of STAT3 (Sherman C T, Brasier A R. Role of signal transducers and activators of transcription 1 and −3 in inducible regulation of the human angiotensinogen gene by interleukin-6. Mol Endocrinol 2001; 15:441-457). The phospho-STAT3Tyr705 protein will dimerize and form an activated nuclear transcription complex that will subsequently translocate into the nucleus to regulate the target genes (Sherman C T, Brasier A R. Role of signal transducers and activators of transcription 1 and −3 in inducible regulation of the human angiotensinogen gene by interleukin-6. Mol Endocrinol 2001; 15:441-457). Since UVB can induce IL-6 expression, whether UVB can induce phosphorylation of STAT3 was further tested. Using immunoblotting, it was found that UVB radiation slightly increased STAT3 phosphorylation on Tyr705. The result also showed that TA substantially attenuated UVB-induced STAT3 phosphorylation in RPE (
Effect of TA or JAK2 Inhibitor on UVB-Induced CFB mRNA
Whether UVB can induce CFB mRNA expression was determined, and the results showed that the maximal CFB mRNA expression was detected at 10 mJ/cm2 UVB radiation (
One skilled in the art readily appreciates that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The cells, and processes and methods for producing them are representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Modifications therein and other uses will occur to those skilled in the art. These modifications are encompassed within the spirit of the invention and are defined by the scope of the claims.
It will be readily apparent to a person skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention.
All patents and publications mentioned in the specification are indicative of the levels of those of ordinary skill in the art to which the invention pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.
The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations, which are not specifically disclosed herein. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.
